Investors Investors

Stock Quote

Stock Quote

9:01 AM EDT on Jul 17

Press Releases

Press Releases

All Releases
Jul 17, 2019
BRIDGEWATER, N.J. and NEW YORK , July 17, 2019 /PRNewswire/ --  Bausch Health Companies Inc. (NYSE/TSX: BHC) (" Bausch Health " or the "Company") and Progenics Pharmaceuticals (NASDAQ: PGNX), announced today that the U.S. District Court of New Jersey upheld the validity and determined Actavis'
Jul 12, 2019
Commences Search Process to Identify New Board Candidates, Welcomes Input from All Shareholders NEW YORK , July 12, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and
Jul 08, 2019
The Progenics 2019 Annual Meeting is July 11, 2019 NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, encourages all shareholders to
Jul 08, 2019
-Commercial Leader Brings Deep Experience in Radiopharmaceuticals and Oncology- NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today
Jul 01, 2019
Glass Lewis Believes Velan’s “Fundamental Operational and Corporate Governance  Case Fails to Bear Fruit” Glass Lewis Agrees the Current Settlement Offer is Fair and “Would Grant Velan Direct Board Representation Twice the Size of its Economic Interest” Glass Lewis Supports Progenics’ Strategy and
Jun 28, 2019
Comments on ISS Report Urges Shareholders to Vote “FOR” All of the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 28, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted
Jun 27, 2019
Velan Rebuffed Very Reasonable Offer that Included a One Year Standstill, Designating Two New Independent Directors and an Incumbent Director Not Standing for Re-election in 2020 Despite Progenics’ Repeated Settlement Concessions, Velan Insists on Terms to Position it for Control as Soon as
Jun 25, 2019
NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that results from studies highlighting the PSMA-targeted imaging
Jun 24, 2019
Oral Presentation of Progenics’ PSMA AI Technology at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and
Jun 24, 2019
Board has Positioned Progenics to Maximize Value as a Result of Proactive and Deliberate Strategy Velan’s Baseless Criticisms about the Development of AZEDRA and 1095 Reveal a Fundamental Lack of Understanding of Radiopharmaceuticals Shareholders Should Question Velan’s Qualifications and Be
Jun 20, 2019
NEW YORK, June 20, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the Company has reached
Jun 19, 2019
Highlights Velan’s Faulty Assertions and Ongoing Efforts to Mislead Progenics Shareholders Urges Shareholders to Vote “For” All of Company’s Directors on the WHITE Proxy Card NEW YORK, June 19, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an
Jun 18, 2019
aBSI Leverages Artificial Intelligence to Automatically and Reliably Analyze Bone Scan Images from Prostate Cancer Patients NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and artificial intelligence to
Jun 13, 2019
Asks Shareholders to Vote “FOR” All the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial
Jun 13, 2019
NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the first patient has been dosed in the Company’s Phase 2
Jun 06, 2019
NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced today announced that six abstracts highlighting AZEDRA (iobenguane I
Jun 03, 2019
  - Long-Term Follow Up Data from Pivotal Study Presented at ASCO - - Patients Treated with AZEDRA Show Overall Survival of 73.1% at Two Years and 44.2% at Four Years - NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing
Jun 03, 2019
Asks Shareholders to Vote “FOR” All the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial
May 30, 2019
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at the
May 23, 2019
NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that four abstracts highlighting AZEDRA (iobenguane I 131) and PyL (